4D Molecular Therapeutics (NASDAQ:FDMT) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

4D Molecular Therapeutics (NASDAQ:FDMTGet Rating) posted its quarterly earnings data on Thursday. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.01), MarketWatch Earnings reports.

Shares of NASDAQ:FDMT traded down $0.41 during trading on Friday, hitting $9.01. 412,801 shares of the company were exchanged, compared to its average volume of 180,019. The firm’s 50 day moving average price is $13.55 and its 200-day moving average price is $17.27. 4D Molecular Therapeutics has a 12-month low of $8.93 and a 12-month high of $36.14.

A number of institutional investors and hedge funds have recently bought and sold shares of FDMT. BlackRock Inc. boosted its holdings in 4D Molecular Therapeutics by 2.0% in the 1st quarter. BlackRock Inc. now owns 2,130,226 shares of the company’s stock worth $32,208,000 after acquiring an additional 42,544 shares during the period. Vanguard Group Inc. boosted its stake in shares of 4D Molecular Therapeutics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,290,941 shares of the company’s stock valued at $19,519,000 after buying an additional 7,858 shares during the last quarter. State Street Corp boosted its stake in shares of 4D Molecular Therapeutics by 294.1% during the 4th quarter. State Street Corp now owns 1,259,660 shares of the company’s stock valued at $27,637,000 after buying an additional 939,998 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of 4D Molecular Therapeutics by 41.0% during the 4th quarter. Geode Capital Management LLC now owns 482,437 shares of the company’s stock valued at $10,584,000 after buying an additional 140,219 shares during the last quarter. Finally, Morgan Stanley boosted its stake in shares of 4D Molecular Therapeutics by 58.3% during the 2nd quarter. Morgan Stanley now owns 430,787 shares of the company’s stock valued at $10,374,000 after buying an additional 158,641 shares during the last quarter. 76.60% of the stock is owned by hedge funds and other institutional investors.

Separately, Zacks Investment Research downgraded shares of 4D Molecular Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, April 6th.

About 4D Molecular Therapeutics (Get Rating)

4D Molecular Therapeutics, Inc, a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.

Featured Articles

Earnings History for 4D Molecular Therapeutics (NASDAQ:FDMT)

Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.